Novartis Pipeline
Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.
Download the Compounds in development (PDF 0.1 MB) section of the 2025 Annual Report
-
LXE408LXE408ChagasIn-market Brands and Global Health Phase 2 Proteasome inhibitor
-
LXE408LXE408Visceral leishmaniosisIn-market Brands and Global Health Phase 2 ≥ 2029 Proteasome inhibitorLead Indication
-
MAA868abelacimabAtrial fibrillationCardiovascular, Renal and Metabolic Phase 3 2028 FXI inhibitorLead Indication
-
MAS825MAS825Still’s diseaseImmunology Phase 2 IL18 Inhibitor, IL1BLead Indication
-
NIO752NIO752Progressive supranuclear palsyNeuroscience Phase 1 Tau antisense oligonucleotideLead Indication
-
NIO752NIO752Alzheimer’s diseaseNeuroscience Phase 1 Tau antisense oligonucleotide
-
OJR520OJR520CKDCardiovascular, Renal and Metabolic Phase 1Lead Indication
-
OMB157Kesimpta®Multiple sclerosis, new dosing regimenNeuroscience Phase 3 2027 CD20 antagonistSupplementary Indication
-
OMB157Kesimpta®Multiple sclerosis, pediatricsNeuroscience Phase 3 2026 CD20 antagonistSupplementary Indication
-
PAC001PAC001ASCVDpacibekitugCardiovascular, Renal and Metabolic Phase 2 ≥ 2029 Anti-IL-6 mAbLead Indication
-
PAC001PAC001Thyroid eye disease (TED)pacibekitugOthers Phase 2 Anti-IL-6 mAb
-
PIT565PIT565Systemic lupus erythematosusImmunology Phase 1 Anti-CD19, Anti-CD2, Anti-CD3
-
PIT565PIT565Rheumatoid arthritisImmunology Phase 1 Anti-CD19, Anti-CD2, Anti-CD3
-
PKC412Rydapt®Acute myeloid leukemia, pediatricsIn-market Brands and Global Health Phase 2 2027 Multi-targeted kinase inhibitorSupplementary Indication
-
PKN605PKN605HDAC6 InhibitorCardiovascular, Renal and Metabolic Phase 2 Atrial FibrillationLead Indication
-
QCZ484QCZ484HypertensionCardiovascular, Renal and Metabolic Phase 2 ≥ 2029Lead Indication
-
QMF149Atectura®Asthma, pediatricsIn-market Brands and Global Health Phase 3 2028 LABA + ICSSupplementary Indication
-
SEG101Adakveo®Sickle cell disease, pediatricsIn-market Brands and Global Health Phase 3 ≥ 2029 P-selectin inhibitorSupplementary Indication
-
TIN816TIN816Acute kidney injuryCardiovascular, Renal and Metabolic Phase 2 ATP modulatorLead Indication
-
TQJ230pelacarsenCVRR (secondary prevention) in patients with elevated Lp(a)Cardiovascular, Renal and Metabolic Phase 3 2026 ASO targeting Lp(a)Lead Indication
Pagination
Disclaimer
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.
In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.